Global Cord Blood Corporation
Other OTCTotal Valuation
Global Cord Blood Corporation carries a market capitalization of 127.22M, placing it among publicly traded companies globally. Its enterprise value stands at -3.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 127.22M |
| Enterprise Value | -3.68B |
Share Statistics
Global Cord Blood Corporation currently has 121.55M shares outstanding.
| Shares Outstanding | 121.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Global Cord Blood Corporation trades at a trailing price-to-earnings ratio of 5.93. The price-to-sales ratio is 2.39, and the price-to-book ratio stands at 1.03.
| PE Ratio | 5.93 |
| PS Ratio | 2.39 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Global Cord Blood Corporation maintains a current ratio of 10.73, meaning it holds 10.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.73 |
| Quick Ratio | 10.64 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
Global Cord Blood Corporation posts a return on equity of 19.00 and a return on invested capital of 10.92.
| Return on Equity (ROE) | 19.00 |
| Return on Assets (ROA) | 6.10 |
| Return on Invested Capital (ROIC) | 10.92 |
| Return on Capital Employed (ROCE) | 18.63 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.07 |
Taxes
Over the trailing twelve months, Global Cord Blood Corporation has paid 118.35M in income taxes, reflecting an effective tax rate of 18.85.
| Income Tax | 118.35M |
| Effective Tax Rate | 18.85 |
Stock Price Statistics
Global Cord Blood Corporation's stock has declined approximately -5% over the past 52 weeks. The 50-day moving average sits at 0.94, while the 200-day moving average is 0.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 0.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Global Cord Blood Corporation generated 1.24B in revenue and converted that into 501.07M in net income, yielding earnings per share of 4.19. EBITDA reached 608.87M, while operating income came in at 608.87M.
| Revenue | 1.24B |
| Gross Profit | 1.06B |
| Operating Income | 608.87M |
| Pretax Income | 627.84M |
| Net Income | 501.07M |
| EBITDA | 608.87M |
| EBIT | 608.87M |
| Earnings Per Share (EPS) | 4.19 |
Balance Sheet
Global Cord Blood Corporation holds 6.66B in cash and equivalents against 147,000.00 in total debt, resulting in a net debt position of -6.66B. Total book value stands at 2.89B, with working capital of 6.29B providing operational flexibility.
| Cash & Cash Equivalents | 6.66B |
| Total Debt | 147,000.00 |
| Net Debt | -6.66B |
| Equity (Book Value) | 2.89B |
| Book Value Per Share | 23.74 |
| Working Capital | 6.29B |
Margins
Global Cord Blood Corporation operates with a gross margin of 85.26, reflecting its pricing power and cost economics. The operating margin of 48.97 and net profit margin of 40.30 provide insight into operational efficiency.
| Gross Margin | 85.26 |
| Operating Margin | 48.97 |
| Pretax Margin | 50.50 |
| Profit Margin | 40.30 |
| EBITDA Margin | 48.97 |
Scores
Global Cord Blood Corporation posts an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.24 |